Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021
26 juil. 2021 09h00 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the...
Harrow Health Granted Two Patents for Novel Surgical Dilation Formulation
15 juil. 2021 08h00 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., July 15, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) an ophthalmic-focused healthcare company, today announced that the United States Patent and Trademark Office...
Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026
17 juin 2021 16h01 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., June 17, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of...
Harrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026
14 juin 2021 17h59 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the pricing of...
Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones
14 juin 2021 07h45 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that it has...
Harrow Health Launches New Corporate and Investor Website
01 juin 2021 09h00 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the launch of its...
Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx’s Proprietary Klarity-C® Drops
17 mai 2021 09h00 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., May 17, 2021 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business and a wholly owned subsidiary of...
Harrow Health Announces Record First Quarter 2021 Financial Results
11 mai 2021 16h01 HE
|
Harrow Health, Inc.
Highlights for First Quarter 2021: Revenues of $15.4 million, a 31% increase compared with $11.8 million for prior year;Adjusted EBITDA(1), a non-GAAP measure, reached a new high of $4.3 million,...
Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock
05 mai 2021 16h03 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., May 05, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that the Company...
Harrow Health Announces Full Exercise and Closing of Option to Purchase Additional Senior Notes
05 mai 2021 16h01 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., May 05, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of an...